We analysed the guidelines for testosterone therapy (TTh) produced by major international medical societies including: the American Urological Association, European Association of Urology, American Association of Clinical Endocrinologists, British Society for Sexual Medicine, Endocrine Society, International Society for Sexual Medicine, and the International Society for the Study of the Aging Male, and compared their recommendations.
All the organisations were in general agreement concerning the following key points:
- Only men meeting the criteria for testosterone deficiency (TD) should be treated.
- Consider screening asymptomatic men with certain conditions that increase the risk of TD.
- Exogenous TTh causes impairment of spermatogenesis.
- There is no evidence that TTh causes prostate cancer.
- Men on TTh require careful laboratory monitoring.